CNSY (36) GUTS (52) SINT (37) PAVM (31) ⌘ Pro Terminal →

Cytosorbents Corporation (CTSO) — RQD Stock Rating Cockpit

$4.40 -16.03% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.26

Cytosorbents Corporation (CTSO) carries a Roarable Rating of E (Strong Sell) with 21/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (21/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $13.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.26 (-3.08%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (21/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-16.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CTSO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (21/100 Composite)

🔍 WHY CTSO SCORES 21/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+6/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+5/20 pts (24% of score)

FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 47.9 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.79+8.4% Next Q

Q2 (-2Q)

Grade E$4.11+28.2% Next Q

Q3 (-1Q)

Grade E$5.27-16.5% Next Q

Current

Grade E$4.40-11.6% Hist 90D α

Trajectory: E (15) → E (21)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CTSO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CTSO currently carries a cautious 21/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.30) and Max Pain ($4.62) forces dealer call-delta covering toward $17.85.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CTSO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CTSO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 21%NO 79%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

47.930 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE11% OF RANGE

L: $3$4.40H: $17

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 6 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 11 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on CTSO

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (20)

-35.0% ROIC with 71.5% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (30)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (18)

6/40 institutional & smart-money positioning score with 5/20 macro alignment.

Bull Case: Why Buyers Like CTSO

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTSO)

✓Walkthrough of CTSO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CTSO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -63.93%▼ DESCENDING CHANNEL

2026-10-30O $4.39H $4.70L $4.35C $4.40VOL 24.1K

RES: $6.53SUP: $1.99SMA50: $5.30SMA200: $9.49

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CTSO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CTSO Butterfly Map → + Track CTSO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CTSO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CTSO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CTSO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTSO)

Health Care Rank #1012 of 1016 ⚔️ CNSY vs CTSO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CTSO vs. CNSY, GUTS, SINT, PAVM)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cytosorbents Corporation (CTSO) ranks #1012 by composite RQD confidence (21/100, grade E) and #864 by equity capitalization ($13.9M). Within this direct 5-issuer industry benchmark cohort, CTSO leads on earnings valuation at N/A trailing P/E, while CTSO leads on capital efficiency and profitability with -35.0% ROIC and 71.5% gross margin. GUTS currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with CTSO at 21/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CTSO ACTIVE Cytosorbents Corporation	E	21/100	—	71.5%	-35.0%	-16.03%	$13.9M	Benchmark Subject
CNSY Cerenome Inc.	D-	36/100	—	—	-35.0%	0.00%	$13.2M	/cnsy-vs-ctso →
GUTS Fractyl Health Inc.	D+	52/100	—	—	-35.0%	+11.40%	$13.2M	/guts-vs-ctso →
SINT SiNtx Technologies Inc.	D-	37/100	—	45.3%	-35.0%	-1.15%	$13.0M	/sint-vs-ctso →
PAVM PAVmed Inc.	E	31/100	—	-30.0%	-35.0%	-5.29%	$15.8M	/pavm-vs-ctso →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001175151

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cytosorbents Corporation (CTSO) reported GAAP revenue of $37.1M (+4.1% vs. FY2024 revenue of $35.6M ) , GAAP net income of -$8.2M, operating cash flow of -$12.4M, and free cash flow of -$12.5M (+14.8% YoY). On the balance sheet, CTSO closed FY2025 with $44.2M in total assets against $16.7M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$37.1M	-$8.2M	-$12.4M	-$12.5M	$44.2M	$16.7M
FY2024 (FY)	2024-12-31	$35.6M	-$20.7M	-$14.4M	-$14.7M	$47.4M	$14.0M
FY2023 (FY)	2023-12-31	$0	-$29.2M	-$21.7M	-$21.7M	—	—

3. CTSO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CTSO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Cytosorbents Corporation (NASDAQ: CTSO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $4.40 (-16.03% 1D, market cap $13.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CTSO ranks #1012 in composite RQD confidence.

How does CTSO compare to CNSY and GUTS in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), CTSO carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of 71.5%, and ROIC of -35.0%. By comparison, CNSY (Cerenome Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $13.2M) and GUTS (Fractyl Health Inc.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -35.0%, cap $13.2M). Among the 5-stock peer group, CTSO leads on earnings multiple (N/A) while CTSO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CTSO?

Per CTSO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001175151), Cytosorbents Corporation generated $37.1M in revenue (+4.1% YoY), -$8.2M in net income, and -$12.5M in free cash flow against $44.2M in total assets and $16.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CTSO trading relative to its 50-day, 200-day, and 52-week technical levels?

CTSO last traded at $4.40 (-16.03% on volume of 48,307 shares), positioning the stock -16.98% below its 50-day simple moving average ($5.30) and -53.64% below its 200-day simple moving average ($9.49). Across its 52-week range of $2.84 to $17.00, CTSO sits at the 11.0% percentile with a 14-day RSI of 47.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.85 to $4.95).

CTSO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell CTSO stock right now?

Cytosorbents Corporation (CTSO) currently earns a Roarable Rating of E (Strong Sell — SELL) with 21/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is CTSO's 12-month price target and RQD AI Jury consensus?

CTSO's 12-month base price target is $3.67 (range $2.86 to $17.85), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: CTSO RQD Cockpit CTSO 12M Forecast CTSO Earnings & Move CTSO Dividends & DRIP CTSO Insiders & 13F CTSO Whale Options CTSO Profit Sankey CTSO News & Why